138 In the index

Lanreotide LANR

An FDA-approved long-acting hormone-blocking medication used for a growth-hormone disorder called acromegaly and for certain hormone-secreting tumors. Human studies strongly support its ability to control these excess-hormone conditions.

Also known as Somatuline

Effects Hormonal

Routes Subcutaneous

Legal status Prescription drug

WADA Not listed

Molecular Structure of C₅₄H₆₉N₁₁O₁₀S₂

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C54H69N11O10S2
Molar mass: 1096.3
CAS: 108736-35-2
PubChem CID: 6918011

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 90-120 mg every 4 weeks

Reported range 60-120 mg every 4 weeks

Route Deep subcutaneous injection

Frequency Once every 4 weeks

Duration Chronic/ongoing (as prescribed)

FDA-approved somatostatin analog (Somatuline Depot) for acromegaly and certain neuroendocrine tumors.

Where this comes from FDA prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.